Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUT-less: PDD-TURBT vs WL-TURBT Plus Re-TURBT in NMIBCs
NCT05962541Phase 4Recruiting
- Sponsor
- Sapienza University of Rome
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of hexaminolevulinate in non-muscle-invasive bladder cancer (NMIBC), sponsored by Sapienza University of Rome. Started Dec 2025; status: recruiting.
02
Drugs
hexaminolevulinate
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05962541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962541.